NCT07120282View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

August 15, 2029

Study Completion Date

December 31, 2030

Conditions
Lung Cancer (NSCLC)
Interventions
DRUG

Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group

Tislelizumab 400 mg iv, q6w, for up to 1 year; patients are permitted to receive concurrent adjuvant platinum-based doublet chemotherapy (q3w, up to 4 cycles) starting from the first dose of tislelizumab; during concurrent chemotherapy, a tislelizumab dosage of 200 mg iv, q3w is allowed.

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER